

Richard M Tsai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8514548/publications.pdf>

Version: 2024-02-01

19
papers

2,535
citations

516710

16
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

4327
citing authors

#	ARTICLE	IF	CITATIONS
1	Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome. <i>JAMA Neurology</i> , 2020, 77, 215.	9.0	81
2	Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 335-344.	0.8	73
3	Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy. <i>Molecular Neurodegeneration</i> , 2020, 15, 2.	10.8	69
4	Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	353
5	Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy. <i>NeuroImage: Clinical</i> , 2019, 24, 102025.	2.7	53
6	¹⁸ F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 13.	6.2	121
7	CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. <i>Neurology</i> , 2018, 90, e273-e281.	1.1	75
8	Associations between [¹⁸ F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. <i>Neurology</i> , 2018, 90, e282-e290.	1.1	113
9	Discriminative Accuracy of [¹⁸ F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1151.	7.4	298
10	¹⁸ F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. <i>Annals of Neurology</i> , 2017, 82, 622-634.	5.3	148
11	An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from <i>GRN</i> gene mutations. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 507-512.	3.7	32
12	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. <i>Nature</i> , 2017, 549, 523-527.	27.8	852
13	Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study. <i>PLoS ONE</i> , 2016, 11, e0157218.	2.5	40
14	Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 227-236.	2.6	14
15	Therapy and clinical trials in frontotemporal dementia: past, present, and future. <i>Journal of Neurochemistry</i> , 2016, 138, 211-221.	3.9	109
16	Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 29-35.	2.2	18
17	The Chinese Verbal Learning Test Specifically Assesses Hippocampal State. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2015, 30, 412-416.	1.9	3
18	Clinical Trials: Past, Current, and Future for Atypical Parkinsonian Syndromes. <i>Seminars in Neurology</i> , 2014, 34, 225-234.	1.4	19

#	ARTICLE	IF	CITATIONS
19	Treatment of Frontotemporal Dementia. Current Treatment Options in Neurology, 2014, 16, 319.	1.8	64